IntelliCyt develops innovative, high-throughput, high-content cell- and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery, and in vitro toxicity testing. Founded ...

IntelliCyt has announced a collaboration with Notable Labs to further the development of a predictive personalized medicine platform. Notable Labs helps oncologists identify effective therapies that ...

The Intellicyt® iQue Screener PLUS platform is an integrated instrument, software, and reagent system that enables rapid, high-content, multiplexed analysis of cells and beads in suspension. While ...

Sartorius said today it has acquired IntelliCyt for $90 million cash, in a deal that expands the buyer’s portfolio into bioanalytics by adding the developer of cell screening platforms for drug ...

LONDON (Alliance News) - Contract research organisation Cyprotex PLC on Thursday said it has bought an IntelliCyt iQue screener in order to expand its cell-based services. The screener uses flow ...

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody screening and immuno-oncology research, today announced record sales ...

The event – which takes place in Vancouver, Canada, from June 22 to 26 – will give delegates the chance to explore a smarter way to perform flow cytometry experiments. The iQue3 is designed to provide ...